Hand Dermatitis: A Review of Clinical Features, Prevention and Treatment

American Journal of Clinical Dermatology

Volumn 16, Issue 4, 2015, Pages 257-270

  Antonov, Dimitar ^a   Schliemann, Sibylle ^a   Elsner, Peter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; METHOTREXATE; DERMATOLOGICAL AGENT;

CLINICAL FEATURE; CLINICAL PRACTICE; DERMATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ECZEMA; HAND DERMATITIS; HAND DISEASE; HUMAN; IONIZING RADIATION; IRRITANT DERMATITIS; NUMMULAR DERMATITIS; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PHOTOTHERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; PUVA; REHABILITATION; REVIEW; SECONDARY PREVENTION; SKIN ALLERGY; SKIN PROTECTION; TOPICAL TREATMENT; TREATMENT RESPONSE; ANIMAL; CHRONIC DISEASE; HAND DERMATOSES; INTRADERMAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; ECZEMA; HAND DERMATOSES; HUMANS; PHOTOTHERAPY;

EID: 84938878249     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-015-0130-z     Document Type: Review

References (96)

1. Diepgen TL, Agner T, Aberer W, Berth-Jones J, Cambazard F, Elsner P, et al. Management of chronic hand eczema. Contact Dermatitis. 2007;57(4):203–10. doi:10.1111/j.1600-0536.2007.01179.x.
2. Diepgen T, Elsner P, Schliemann S, Fartasch M, Köllner A, Skudlik C, et al. Management von Handekzemen Leitlinie ICD-10-Ziffer: L20. L23. L24. L25. L30. J Dtsch Dermatol Ges. 2009;7(s3):s1–16.
3. Bissonnette R, Diepgen TL, Elsner P, English J, Graham-Brown R, Homey B, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24(Suppl 3):1–20. doi:10.1111/j.1468-3083.2010.03615.x.
4. Diepgen TL, Andersen KE, Chosidow O, Coenraads PJ, Elsner P, English J, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1–22.
5. English J, Aldridge R, Gawkrodger DJ, Kownacki S, Statham B, White JM, et al. Consensus statement on the management of chronic hand eczema. Clin Exp Dermatol. 2009;34(7):761–9. doi:10.1111/j.1365-2230.2009.03649.x.
6. Menne T, Johansen JD, Sommerlund M, Veien NK, Danish Contact Dermatitis G. Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema. Contact Dermatitis. 2011;65(1):3–12. doi:10.1111/j.1600-0536.2011.01915.x.
7. Elsner P, Schliemann S. Pitfalls and errors in patch testing: suggestions for quality assurance. In: Lachapelle JM, editor. Patch testing tips. Berlin: Springer; 2014. p. 27–35.
8. Scalone L, Cortesi PA, Mantovani LG, Belisari A, Ayala F, Fortina AB, et al. Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. Br J Dermatol. 2015;172(1):187–95. doi:10.1111/bjd.13220.
9. Malten KE. Thoughts on irritant contact dermatitis. Contact Dermatitis. 1981;7(5):238–47.
10. Freeman S, Maibach H. Study of irritant contact dermatitis produced by repeat patch test with sodium lauryl sulfate and assessed by visual methods, transepidermal water loss, and laser Doppler velocimetry. J Am Acad Dermatol. 1988;19(3):496–502.
11. Ruppert L, Apfelbacher C, Molin S, Bauer A, Mahler V, Schmitt J, et al. Itching in patients with chronic hand eczema: data from the CARPE registry. Dermatology. 2014;229(2):146–53. doi:10.1159/000362901.
12. Johansen JD, Hald M, Andersen BL, Laurberg G, Danielsen A, Avnstorp C, et al. Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish Contact Dermatitis Group. Contact Dermatitis. 2011;65(1):13–21. doi:10.1111/j.1600-0536.2011.01911.x.
13. Diepgen TL, Andersen KE, Brandao FM, Bruze M, Bruynzeel DP, Frosch P, et al. Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. Br J Dermatol. 2009;160(2):353–8. doi:10.1111/j.1365-2133.2008.08907.x.
14. Molin S, Diepgen TL, Ruzicka T, Prinz JC. Diagnosing chronic hand eczema by an algorithm: a tool for classification in clinical practice. Clin Exp Dermatol. 2011;36(6):595–601. doi:10.1111/j.1365-2230.2010.04001.x.
15. Kutzner H, Wurzel RM, Wolff HH. Are acrosyringia involved in the pathogenesis of “dyshidrosis”? Am J Dermatopathol. 1986;8(2):109–16.
16. Lee WJ, Lee DW, Kim CH, Won CH, Chang SE, Lee MW, et al. Pompholyx with bile-coloured vesicles in a patient with jaundice: are sweat ducts involved in the development of pompholyx? J Eur Acad Dermatol Venereol. 2010;24(2):235–6. doi:10.1111/j.1468-3083.2009.03383.x.
17. Resnik KS, Kantor GR, Lessin SR, Kadin ME, Chooback L, Cooper HS, et al. Mycosis fungoides palmaris et plantaris. Arch Dermatol. 1995;131(9):1052–6.
18. Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol. 2004;18(4):397–415. doi:10.1111/j.1468-3083.2004.00937.x.
19. Wollina U. Pompholyx: what’s new? Expert Opin Investig Drugs. 2008;17(6):897–904. doi:10.1517/13543784.17.6.897.
20. Held E, Mygind K, Wolff C, Gyntelberg F, Agner T. Prevention of work related skin problems: an intervention study in wet work employees. Occup Environ Med. 2002;59(8):556–61.
21. Jungbauer FH, van der Harst JJ, Groothoff JW, Coenraads PJ. Skin protection in nursing work: promoting the use of gloves and hand alcohol. Contact Dermatitis. 2004;51(3):135–40.
22. Flyvholm MA, Mygind K, Sell L, Jensen A, Jepsen KF. A randomised controlled intervention study on prevention of work related skin problems among gut cleaners in swine slaughterhouses. Occup Environ Med. 2005;62(9):642–9. doi:10.1136/oem.2004.016576.
23. Weisshaar E, Radulescu M, Bock M, Albrecht U, Diepgen TL. Educational and dermatological aspects of secondary individual prevention in healthcare workers. Contact Dermatitis. 2006;54(5):254–60.
24. Seyfarth F, Schliemann S, Antonov D, Elsner P. Teaching interventions in contact dermatitis. Dermatitis. 2011;22(1):8–15.
25. Slotosch CM, Kampf G, Loffler H. Effects of disinfectants and detergents on skin irritation. Contact Dermatitis. 2007;57(4):235–41. doi:10.1111/j.1600-0536.2007.01200.x.
26. Kappes UP, Goritz N, Wigger-Alberti W, Heinemann C, Elsner P. Tandem application of sodium lauryl sulfate and n-propanol does not lead to enhancement of cumulative skin irritation. Acta Derm Venereol. 2001;81(6):403–5.
27. Yokota M, Maibach HI. Moisturizer effect on irritant dermatitis: an overview. Contact Dermatitis. 2006;55(2):65–72. doi:10.1111/j.0105-1873.2006.00890.x.
28. Bourke J, Coulson I, English J. Guidelines for the management of contact dermatitis: an update. Br J Dermatol. 2009;160(5):946–54. doi:10.1111/j.1365-2133.2009.09106.x.
29. Kutting B, Baumeister T, Weistenhofer W, Pfahlberg A, Uter W, Drexler H. Effectiveness of skin protection measures in prevention of occupational hand eczema: results of a prospective randomized controlled trial over a follow-up period of 1 year. Br J Dermatol. 2009. doi:10.1111/j.1365-2133.2009.09485.x.
30. Fartasch M, Diepgen TL, Drexler H, Elsner P, Fluhr JW, John SM, et al. Berufliche Hautmittel. 2008. http://www.awmf.org/uploads/tx_szleitlinien/013-056l_S1_Berufliche_Hautmittel_2008.pdf. Accessed 29 Nov 2014.
31. Van Coevorden AM, Coenraads PJ, Svensson A, Bavinck JN, Diepgen TL, Naldi L, et al. Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. Br J Dermatol. 2004;151(2):446–51. doi:10.1111/j.1365-2133.2004.06040.x.
32. De Paepe K, Hachem JP, Vanpee E, Goossens A, Germaux MA, Lachapelle JM, et al. Beneficial effects of a skin tolerance-tested moisturizing cream on the barrier function in experimentally-elicited irritant and allergic contact dermatitis. Contact Dermatitis. 2001;44(6):337–43 (cod440604 [pii]).
33. Ramsing DW, Agner T. Preventive and therapeutic effects of a moisturizer. An experimental study of human skin. Acta Derm Venereol. 1997;77(5):335–7.
34. Loden M. The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol. 2005;19(6):672–88. doi:10.1111/j.1468-3083.2005.01326.x(quiz 86–7).
35. Folster-Holst R, Latussek E. Synthetic tannins in dermatology—a therapeutic option in a variety of pediatric dermatoses. Pediatr Dermatol. 2007;24(3):296–301. doi:10.1111/j.1525-1470.2007.00406.x.
36. Nilsson E, Henning C, Hjorleifsson ML. Density of the microflora in hand eczema before and after topical treatment with a potent corticosteroid. J Am Acad Dermatol. 1986;15(2 Pt 1):192–7.
37. Frosch PJ, Schulze-Dirks A. Contact allergy caused by polidocanol (thesit). Hautarzt. 1989;40(3):146–9.
38. Uter W, Geier J, Fuchs T. Contact allergy to polidocanol, 1992 to 1999. J Allergy Clin Immunol. 2000;106(6):1203–4 (S0091674900870852 [pii]).
39. Veenhuis RT, van Horssen J, Bos RP, Anzion RB, Van Der Valk PG. Highly increased urinary 1-hydroxypyrene excretion rate in patients with atopic dermatitis treated with topical coal tar. Arch Dermatol Res. 2002;294(4):168–71. doi:10.1007/s00403-002-0311-5.
40. Luger T, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, et al. Topical skin therapy with glucocorticoids–therapeutic index. J Dtsch Dermatol Ges. 2004;2(7):629–34.
41. Luger T, Elsner P, Kerscher M, Korting HC, Krutmann J, Niedner R, et al. Topische Dermatotherapie mit Glukokortikoiden—Therapeutischer Index. ICD 10: L20. In: Leitlinien der Deutschen Dermatologischen Gesellschaft (DDG). Düsseldorf. 2009. http://www.derma.de/fileadmin/derma/pdfs/ll_glukokortikoide.pdf. Accessed 29 Nov 2014.
42. Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140(5):882–6 (bjd2819 [pii]).
43. Hachem JP, De Paepe K, Vanpee E, Kaufman L, Rogiers V, Roseeuw D. Combination therapy improves the recovery of the skin barrier function: an experimental model using a contact allergy patch test combined with TEWL measurements. Dermatology. 2001;202(4):314–9 (drm02314 [pii]).
44. Corticosteroids Isaksson M. Dermatol Ther. 2004;17(4):314–20. doi:10.1111/j.1396-0296.2004.04036.x.
45. Isaksson M, Bruze M. Repetitive usage testing with budesonide in experimental nickel–allergic contact dermatitis in individuals hypersensitive to budesonide. Br J Dermatol. 2001;145(1):38–44 (bjd4279 [pii]).
46. Uter W, de Padua CM, Pfahlberg A, Nink K, Schnuch A, Lessmann H. Contact allergy to topical corticosteroids–results from the IVDK and epidemiological risk assessment. J Dtsch Dermatol Ges. 2009;7(1):34–41, 34–42. doi:10.1111/j.1610-0387.2008.06844.x.
47. Luger T, Paul C. Potential new indications of topical calcineurin inhibitors. Dermatology. 2007;215(Suppl 1):45–54. doi:10.1159/000102119.
48. Schliemann S, Kelterer D, Bauer A, John SM, Skudlik C, Schindera I, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis. 2008;58(5):299–306. doi:10.1111/j.1600-0536.2007.01314.x.
49. Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 2000;42(6):349–50.
50. Thelmo MC, Lang W, Brooke E, Osborne BE, McCarty MA, Jorizzo JL, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatol Treat. 2003;14(3):136–40 (ECGNGAJB45URRKDW [pii]).
51. Ring J, Barker J, Behrendt H, Braathen L, Darsow U, Dubertret L, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol. 2005;19(6):663–71. doi:10.1111/j.1468-3083.2005.01315.x.
52. Belsito DV, Fowler JF Jr, Marks JG Jr, Pariser DM, Hanifin J, Duarte IA, et al. Pimecrolimus cream 1 %: a potential new treatment for chronic hand dermatitis. Cutis. 2004;73(1):31–8.
53. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondo D, Bilker WB. Association between malignancy and topical use of pimecrolimus. JAMA Dermatol. 2015. doi:10.1001/jamadermatol.2014.4305.
54. Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema–an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges. 2009;7(2):117–21. doi:10.1111/j.1610-0387.2008.06772.x.
55. Bauer A, Lange N, Matterne U, Meurer M, Braeutigam M, Diepgen TL. Efficacy of pimecrolimus 1 % cream in the long term management of atopic hand dermatitis. A double-blind RCT. J Dtsch Dermatol Ges. 2012;10(6):426–33. doi:10.1111/j.1610-0387.2011.07832.x.
56. Brasch J, Becker D, Aberer W, Bircher A, Kranke B, Denzer-Furst S, et al. Contact dermatitis. J Dtsch Dermatol Ges. 2007;5(10):943–51. doi:10.1111/j.1610-0387.2007.06523.x.
57. Jensen L, Stensgaard A, Andersen KE. Psoralen plus ultraviolet A (PUVA) soaks and UVB TL01 treatment for chronic hand dermatoses. Dermatol Rep. 2012;4(1):e3. doi:10.4081/dr.2012.e3.
58. Hölzle E, Gollnick H, Herzinger T, Hönigsmann H, Lehmann P, Meffert H, et al. Empfehlungen zur Phototherapie und Photochemotherapie. 2002. http://www.awmf.org/uploads/tx_szleitlinien/013-029-abgelaufen.pdf. Accessed 29 Nov 2014.
59. Schempp CM, Muller H, Czech W, Schopf E, Simon JC. Treatment of chronic palmoplantar eczema with local bath-PUVA therapy. J Am Acad Dermatol. 1997;36(5 Pt 1):733–7 (S0190-9622(97)80326-X [pii]).
60. Behrens S, von Kobyletzki G, Gruss C, Reuther T, Altmeyer P, Kerscher M. PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. Photodermatol Photoimmunol Photomed. 1999;15(2):47–51.
61. Stege H, Berneburg M, Ruzicka T, Krutmann J. Cream PUVA photochemotherapy. Hautarzt. 1997;48(2):89–93.
62. Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol. 2003;28(6):584–7 (1378 [pii]).
63. Petering H, Breuer C, Herbst R, Kapp A, Werfel T. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol. 2004;50(1):68–72. doi:10.1016/S0190.
64. Schmidt T, Abeck D, Boeck K, Mempel M, Ring J. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol. 1998;78(4):318–9.
65. Stege H. Ultraviolet therapy in patients with chronic hand eczema. Hautarzt. 2008;59(9):696–702. doi:10.1007/s00105-008-1558-3.
66. van Coevorden AM, Kamphof WG, van Sonderen E, Bruynzeel DP, Coenraads PJ. Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. Arch Dermatol. 2004;140(12):1463–6. doi:10.1001/archderm.140.12.1463.
67. Bayerl C, Gabea A, Peiler D, Rzany B, Allgäuer T, Kleesz P, et al. Pilotstudie zur Therapie des beruflich bedingten Handekzems mit einer neuen tragbaren UVB-Bestralungseinheit. Aktuelle Derm. 1999;25:302–5.
68. Fairris GM, Jones DH, Mack DP, Rowell NR. Superficial X-ray therapy in the treatment of constitutional eczema of the feet. Br J Dermatol. 1984;111(4):500–2.
69. Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis. 2006;17(4):165–81.
70. NICE. Grenz rays therapy for inflammatory skin conditions. 2007. http://guidance.nice.org.uk/IPG236. Accessed 29 Nov 2014.
71. Warner JA, Cruz PD Jr. Grenz ray therapy in the new millennium: still a valid treatment option? Dermatitis. 2008;19(2):73–80.
72. Fairris GM, Jones DH, Mack DP, Rowell NR. Conventional superficial X-ray versus Grenz ray therapy in the treatment of constitutional eczema of the hands. Br J Dermatol. 1985;112(3):339–41.
73. Bollag W, Ott F. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology. 1999;199(4):308–12 (drm99308 [pii]).
74. Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008;17(3):437–43. doi:10.1517/13543784.17.3.437.
75. Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808–17. doi:10.1111/j.1365-2133.2008.08487.x.
76. Reymann F. Two years’ experience with Tigason treatment of pustulosis palmo-plantaris and eczema keratoticum manuum. Dermatologica. 1982;164(3):209–16.
77. Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol. 2004;150(3):545–53. doi:10.1046/j.1365-2133.2003.05729.x.
78. Thestrup-Pedersen K, Andersen KE, Menne T, Veien NK. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. Acta Derm Venereol. 2001;81(5):353–5.
79. Reitamo S, Granlund H. Cyclosporin A in the treatment of chronic dermatitis of the hands. Br J Dermatol. 1994;130(1):75–8.
80. Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol. 1996;76(5):371–6.
81. Mrowietz U, Eberhard Klein C, Reich K, Rosenbach T, Ruzicka T, Sebastian M, et al. Therapie mit Ciclosporin in der Dermatologie. 2000. http://www.derma.de/fileadmin/derma/pdfs/ll_ciclosporin.pdf. Accessed 29 Nov 2014.
82. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema—a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–19. doi:10.1111/j.1468-3083.2006.02023.x.
83. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358(9287):1042–5. doi:10.1016/S0140-6736(01)06179-7.
84. Vakeva L, Reitamo S, Pukkala E, Sarna S, Ranki A. Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. Acta Derm Venereol. 2008;88(2):117–20. doi:10.2340/00015555-0360.
85. Verma KK, Mahesh R, Srivastava P, Ramam M, Mukhopadhyaya AK. Azathioprine versus betamethasone for the treatment of parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol. 2008;74(5):453–7.
86. Verma KK, Bansal A, Sethuraman G. Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol. 2006;72(1):24–7.
87. Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther. 2007;20(4):206–15. doi:10.1111/j.1529-8019.2007.00134.x.
88. Anstey AV, Wakelin S, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004;151(6):1123–32. doi:10.1111/j.1365-2133.2004.06323.x.
89. Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. 1999;40(4):612–4 (S0190-9622(99)70446-9 [pii]).
90. Shaffrali FC, Colver GB, Messenger AG, Gawkrodger DJ. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol. 2003;48(3):417–9. doi:10.1067/mjd.2003.137.
91. Pickenacker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol. 1998;134(3):378–9.
92. Bagot M, Terki N, Bacha S, Moyse D, Suck C, Revuz J. Per os desensitization in nickel contact eczema: a double-blind placebo-controlled clinico-biological study. Ann Dermatol Venereol. 1999;126(6–7):502–4 (MDOI-AD-06-1999-126-6-7-0151-9638-101019-ART4 [pii]).
93. Handa S, Sahoo B, Sharma VK. Oral hyposensitization in patients with contact dermatitis from Parthenium hysterophorus. Contact Dermatitis. 2001;44(5):279–82 (cod440505 [pii]).
94. Sharma AD. Relationship between nickel allergy and diet. Indian J Dermatol Venereol Leprol. 2007;73(5):307–12.
95. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008;17(12):1063–72.
96. Weisshaar E, Kallen U, Weiss M. “The itching hand”—important differential diagnoses and treatment. J Dtsch Dermatol Ges. 2013;11(1):31–42. doi:10.1111/j.1610-0387.2012.08002.x.